Silexion Therapeutics (SLXN) Return on Capital Employed (2024 - 2026)
Silexion Therapeutics (SLXN) posted quarterly Return on Capital Employed of 688.72% for Q1 2026, down 28217.0% year-over-year from N/an in Q1 2025, and down 294.13% quarter-over-quarter from 174.75% in Q4 2025.
Silexion Therapeutics (SLXN) Return on Capital Employed (2024 - 2026) Analysis & Trends
Silexion Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 688.72% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 28217.0% year-over-year to 688.72%; the TTM figure through Mar 2026 stood at 688.72% (down 28217.0% YoY), while the FY2025 annual figure was 509.95%, up 183320.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 688.72%, down from 174.75% in the prior quarter.
- The five-year high for Return on Capital Employed was 2293.98% in Q4 2024, with the low at 869.28% in Q2 2024.
- The 3-year median for Return on Capital Employed is 228.83% (2025), against an average of 140.42%.
- Peak annual rise in Return on Capital Employed reached 58637 bps in 2025, while the deepest fall reached 246872 bps in 2025.
- Silexion Therapeutics' Return on Capital Employed stood at 2293.98% in 2024, then tumbled by 108 bps to 174.75% in 2025, then sank by 294 bps to 688.72% in 2026.
- Business Quant data shows SLXN's Return on Capital Employed at 688.72% in Q1 2026, 174.75% in Q4 2025, and 154.17% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | -3,153.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,153.35% |
| Mar 31, 2026 | -688.72% |
| Dec 31, 2025 | -174.75% |
| Sep 30, 2025 | -154.17% |
| Jun 30, 2025 | -282.92% |
| Mar 31, 2025 | -406.55% |
| Dec 31, 2024 | 2,293.98% |
| Sep 30, 2024 | 1,405.78% |
| Jun 30, 2024 | -869.28% |